Corrigendum: Analysis of platelet parameters and activation markers in hematologic metastases of lung cancer

Abstract

(Suppl 10):x151–x157. doi: 10.1093/annonc/mds359. 6. Thanopoulou E, Judson I. Hormonal therapy in gynecological sarcomas. Expert Rev Anticancer Ther 2012;12:885–894. doi: 10.1586/era.12.74. 7. Dos Santos LA, Garg K, Diaz JP, Soslow RA, Hensley ML, Alektiar KM, et al. Incidence of lymph node and adnexal metastasis in endometrial stromal sarcoma. Gynecol Oncol 2011;121:319–322. doi: 10.1016/j.ygyno.2010.12.363. 8. Zhou J, Zheng H, Wu SG, He ZY, Li FY, Su GQ, et al. Influence of different treatment modalities on survival of patients with low-grade endometrial stromal sarcoma: a retrospective cohort study. Int J Surg 2015;23:147–151. doi: 10.1016/j.ijsu.2015.09.072. 9. Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008;44:808–818. doi: 10.1016/j. ejca.2008.01.019. 10. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer statistics. Available from: https://seer. cancer.gov/. [Accessed November 16, 2017] 11. Matsuo K, Machida H, Shoupe D, Melamed A, Muderspach LI, Roman LD, et al. Ovarian conservation and overall survival in young women with early-stage cervical cancer. Obstet Gynecol 2017;129:139–151. doi: 10.1097/AOG.0000000000001754. 12. Schick U, Bolukbasi Y, Thariat J, Abdahbortnyak R, Kuten A, Igdem S, et al. Outcome and prognostic factors in endometrial stromal tumors: a Rare Cancer Network study. Int J Radiat Oncol Biol Phys 2012;82:e757–e763. doi: 10.1016/j.ijrobp.2011.11.005.